Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4450657 | 1.00 | PTPN1 (0.36) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| SCHEMBL19547127 | 0.81 | PTPN1 (0.37) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| SCHEMBL727947 | 0.77 | PTPN1 (0.34) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| SCHEMBL994818 | 0.77 | PTPN1 (0.37) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| SCHEMBL28887375 | 0.77 | PTPN1 (0.34) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| Biphenyl SCHEMBL28193720 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28814401 | 0.75 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16334266 | 0.72 | MEN1 (0.31) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30564919 | 0.71 | PTPN1 (0.33) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| Hydrochloric Acid SCHEMBL21835548 | 0.71 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126407-B1 | SPACER GROUPS FOR FUNCTIONALIZED RESINS IN TIRES | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-08-03 | — | — | EP | claimed |
| EP-3077433-B1 | FUNCTIONALIZED RESINS FOR HIGH PERFORMANCE TIRES | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-04-20 | — | — | EP | claimed |
| US-10384987-B2 | 1,3-butadiene synthesis | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-08-20 | — | — | US | claimed |
| EP-3233768-B1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-02-20 | — | — | EP | claimed |
| US-9840569-B2 | Spacer groups for functionalized resins in tires | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-12-12 | — | — | US | claimed |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-16 | — | — | US | claimed |
| EP-2897992-B1 | FUNCTIONALIZED RESINS OBTAINED VIA OLEFIN METATHESIS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2017-11-08 | — | — | EP | claimed |
| US-20170051085-A1 | Spacer Groups for Functionalized Resins in Tires | EXXONMOBIL CHEMICAL PATENTS INC. | 2017-02-23 | — | — | US | claimed |
| EP-3087105-A1 | METHOD FOR CONTROLLED METATHESIS DEPOLYMERIZATION OF SYNTHETIC RUBBER IN A SOLUTION | Compagnie Générale des Etablissements Michelin (FR) | 2016-11-02 | — | — | EP | claimed |
| US-20160289352-A1 | Functionalized Resins for High Performance Tires | EXXONMOBIL CHEMICAL PATENTS INC. | 2016-10-06 | — | — | US | claimed |
| US-9181360-B2 | Polymers prepared by ring opening / cross metathesis | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-11-10 | — | — | US | claimed |
| WO-2015097192-A1 | METHOD FOR CONTROLLED METATHESIS DEPOLYMERIZATION OF SYNTHETIC RUBBER IN A SOLUTION | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2015-07-02 | — | — | WO | claimed |
| US-8669330-B2 | Olefin triblock polymers via ring-opening metathesis polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20130281626-A1 | Polyolefin Compositions and Methods of Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2013-10-24 | — | — | US | claimed |
| US-8461223-B2 | Microporous polycyclopentadiene-based aerogels | ASPEN AEROGELS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20130041122-A1 | Polymers Prepared By Ring Opening / Cross Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2013-02-14 | — | — | US | claimed |
| US-8283419-B2 | Olefin functionalization by metathesis reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-10-09 | — | — | US | claimed |
| US-20120245290-A1 | Diblock Copolymers Prepared by Cross Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | claimed |
| US-20060229374-A1 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | MIDCAP FUNDING IV TRUST | 2006-10-12 | — | — | US | claimed |
| EP-4737444-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250179004-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12202782-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4484435-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4065567-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240109851-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4247783-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230220179-A1 | Processes for Producing Cyclic Olefins from Polymers and Re-Polymerization Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4157813-A1 | PROCESSES FOR PRODUCING CYCLIC OLEFINS FROM POLYMERS AND RE-POLYMERIZATION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-4065567-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3126407-B1 | SPACER GROUPS FOR FUNCTIONALIZED RESINS IN TIRES | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220177409-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022108984-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11325891-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3077433-B1 | FUNCTIONALIZED RESINS FOR HIGH PERFORMANCE TIRES | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021242636-A1 | PROCESSES FOR PRODUCING CYCLIC OLEFINS FROM POLYMERS AND RE-POLYMERIZATION THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210179570-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2021108254-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-10384987-B2 | 1,3-butadiene synthesis | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| EP-2688921-B1 | DIBLOCK COPOLYMERS PREPARED BY CROSS METATHESIS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9884924-B2 | Dual reactive functional groups for resins in tires | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-9840569-B2 | Spacer groups for functionalized resins in tires | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| EP-2897992-B1 | FUNCTIONALIZED RESINS OBTAINED VIA OLEFIN METATHESIS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9776178-B2 | Ruthenium complexes comprising an asymmetrical unsaturated N-heterocyclic diaminocarbene | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) | 2017-10-03 | — | — | US | disclosed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| EP-3214089-A1 | RUTHENIUM COMPLEXES COMPRISING A DISSYMMETRICAL UNSATURATED N-HETEROCYCLIC DIAMINOCARBENE | Ecole Nationale Supérieure De Chimie De Rennes (FR) | 2017-09-06 | — | — | EP | disclosed |
| US-20170226307-A1 | MICROPOROUS POLYOLEFIN-BASED AEROGELS | ASPEN AEROGELS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| WO-2017064680-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SIMEPREVIR SODIUM AND INTERMEDIATE THEREOF | LUPIN LIMITED (IN) | 2017-04-20 | — | — | WO | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| EP-2931736-B1 | RUTHENIUM COMPLEXES COMPRISING AN ASYMMETRICAL UNSATURATED N-HETEROCYCLIC DIAMINOCARBENE | ECOLE NAT SUPÉRIEURE DE CHIMIE DE RENNES (FR) | 2017-03-22 | — | — | EP | disclosed |
| US-20170058057-A1 | Dual Reactive Functional Groups for Resins in Tires | EXXONMOBIL CHEMICAL PATENTS INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170051085-A1 | Spacer Groups for Functionalized Resins in Tires | EXXONMOBIL CHEMICAL PATENTS INC. | 2017-02-23 | — | — | US | disclosed |
| US-9469739-B2 | Microporous polyolefin-based aerogels | ASPEN AEROGELS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160289352-A1 | Functionalized Resins for High Performance Tires | EXXONMOBIL CHEMICAL PATENTS INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160272777-A1 | MICROPOROUS POLYOLEFIN-BASED AEROGELS | MIDCAP FUNDING IV TRUST | 2016-09-22 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9365582-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-14 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-9181360-B2 | Polymers prepared by ring opening / cross metathesis | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315223-A1 | Ruthenium Complexes Comprising an Asymmetrical Unsaturated N-Heterocyclic Diaminocarbene | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2015-11-05 | — | — | US | disclosed |
| EP-2937339-A1 | Macrocylic inhibitors of hepatitis c virus | Janssen Sciences Ireland UC (IE) | 2015-10-28 | — | — | EP | disclosed |
| US-9169334-B2 | Preparation of bottlebrush polymers via ring-opening metathesis polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2322516-B1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R & D IRELAND (IE) | 2015-08-06 | — | — | US | disclosed |
| EP-2897992-A1 | FUNCTIONALIZED RESINS OBTAINED VIA OLEFIN METATHESIS | ExxonMobil Chemical Patents Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9040562-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2015-05-26 | — | — | US | disclosed |
| US-20150141602-A1 | PROCESS FOR TREATING A DICYCLOPENTADIENE MONOMER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-9023808-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2015-05-05 | — | — | US | disclosed |
| US-9024034-B2 | Metathesis catalysts and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| US-8993819-B2 | Process for preparing cycloheptene | BASF SE (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8940839-B2 | Diblock copolymers prepared by cross metathesis | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940940-B2 | Process for preparing macrocyclic ketones | BASF SE (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-8921355-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN R & D IRELAND (IE) | 2014-12-30 | — | — | US | disclosed |
| US-8921436-B2 | Microporous polyolefin-based aerogels | ASPEN AEROGELS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2785763-A1 | FUNCTIONALIZATION OF VINYL TERMINATED POLYMERS BY RING OPENING CROSS METATHESIS | ExxonMobil Chemical Patents Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R&D IRELAND (IE) | 2014-09-11 | — | — | US | disclosed |
| US-8809456-B2 | Polyolefin compositions and methods of production thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014120433-A1 | PREPARATION OF BOTTLEBRUSH POLYMERS VIA RING-OPENING METATHESIS POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140213732-A1 | Preparation of Bottlebrush Polymers via Ring-Opening Metathesis Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2014-07-31 | — | — | US | disclosed |
| US-8785562-B2 | Amphiphilic block polymers prepared by alkene metathesis | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8754106-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-8754116-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8741926-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-03 | — | — | US | disclosed |
| EP-1910404-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8722892-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN R&D IRELAND (IE) | 2014-05-13 | — | — | US | disclosed |
| US-20140113929-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen R&D Ireland (formerly Tibotec Pharmaceuticals) (IE) | 2014-04-24 | — | — | US | disclosed |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| WO-2014047356-A1 | FUNCTIONALIZED RESINS OBTAINED VIA OLEFIN METATHESIS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20140080932-A1 | MICROPOROUS POLYOLEFIN-BASED AEROGELS | ASPEN AEROGELS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2688954-A2 | OLEFIN TRIBLOCK POLYMERS VIA RING-OPENING METATHESIS POLYMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8637663-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-01-28 | — | — | US | disclosed |
| EP-1919904-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN R & D IRELAND (IE) | 2014-01-08 | — | — | EP | disclosed |
| US-20130338402-A1 | PROCESS FOR PREPARING MACROCYCLIC KETONES | BASF SE (DE) | 2013-12-19 | — | — | US | disclosed |
| EP-1913015-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN R & D IRELAND (IE) | 2013-12-11 | — | — | EP | disclosed |
| WO-2013176801-A1 | PROCESS FOR TREATING A DICYCLOPENTADIENE MONOMER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-1910404-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20130281626-A1 | Polyolefin Compositions and Methods of Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| US-8519147-B2 | Carbene complexes of lithium and/or magnesium metal salts, and uses thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| EP-2111396-B1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | JANSSEN R & D IRELAND (IE) | 2013-08-07 | — | — | EP | disclosed |
| US-8461223-B2 | Microporous polycyclopentadiene-based aerogels | ASPEN AEROGELS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013081726-A1 | FUNCTIONALIZATION OF VINYL TERMINATED POLYMERS BY RING OPENING CROSS METATHESIS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | MEDIVIR AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8383584-B2 | HCV inhibiting macrocyclic phenylcarbamates | MEDIVIR AB (SE) | 2013-02-26 | — | — | US | disclosed |
| US-20130041122-A1 | Polymers Prepared By Ring Opening / Cross Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130018205-A1 | PROCESS FOR PREPARING CYCLOHEPTENE | BASF SE (DE) | 2013-01-17 | — | — | US | disclosed |
| US-8349869-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2013-01-08 | — | — | US | disclosed |
| US-8283419-B2 | Olefin functionalization by metathesis reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-10-09 | — | — | US | disclosed |
| WO-2012134713-A2 | OLEFIN TRIBLOCK POLYMERS VIA RING-OPENING METATHESIS POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8278322-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120245290-A1 | Diblock Copolymers Prepared by Cross Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245298-A1 | Amphiphilic Block Polymers Prepared by Alkene Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120238746-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2012-09-20 | — | — | US | disclosed |
| EP-2498908-A2 | METATHESIS CATALYSTS AND PROCESSES FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20120202859-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-09 | — | — | US | disclosed |
| US-8227407-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8216999-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120171157-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2012-07-05 | — | — | US | disclosed |
| EP-2238142-B1 | Macrocyclic indoles as hepatitis c virus inhibitors | JANSSEN R & D IRELAND (IE) | 2012-07-04 | — | — | EP | disclosed |
| US-8212043-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN R&D IRELAND (IE) | 2012-07-03 | — | — | US | disclosed |
| EP-1912996-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN R & D IRELAND (IE) | 2012-06-20 | — | — | EP | disclosed |
| US-8183277-B2 | Inhibitors of HCV replication of formula (I)** Image-1whereinW is a heterocycle of formula** Image-2and the remaining variables are as defined in the specification. | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-8153800-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-12-01 | — | — | US | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| EP-2367813-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-1912997-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-09-14 | — | — | EP | disclosed |
| US-8012939-B2 | Macrocyclic inhibitors of hepatitis C virus | Tibotec Pharmaceuticals Ltd. Co (IE) | 2011-09-06 | — | — | US | disclosed |
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| EP-1912995-B1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| US-20110112304-A1 | Carbene Complexes of Lithium And/Or Magnesium Metal Salts, And Uses Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112302-A1 | Metathesis Catalysts and Processes for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011056884-A2 | CARBENE COMPLEXES OF LITHIUM AND/OR MAGNESIUM METAL SALTS, AND USES THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056874-A2 | METATHESIS CATALYSTS AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| EP-2310396-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | Tibotec Pharmaceuticals (IE) | 2011-04-20 | — | — | EP | disclosed |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1913014-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1919899-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-19 | — | — | EP | disclosed |
| EP-1912999-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-05 | — | — | EP | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
| EP-2238142-A2 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | Tibotec Pharmaceuticals (IE) | 2010-10-13 | — | — | EP | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
| US-20100173939-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010075127-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| EP-2121674-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARM LTD (IE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | MEDIVIR AB | 2010-02-18 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| US-20100022578-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-28 | — | — | US | disclosed |
| EP-1912981-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2010-01-20 | — | — | EP | disclosed |
| WO-2010003658-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2010-01-14 | — | — | WO | disclosed |
| US-20090318647-A1 | Olefin Functionalization By Metathesis Reaction | EXXONMOBIL CHEMICAL PATENTS INC. | 2009-12-24 | — | — | US | disclosed |
| EP-2121674-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Tibotec Pharmaceuticals (IE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2118091-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | Tibotec Pharmaceuticals (IE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-11-12 | — | — | US | disclosed |
| EP-2111396-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | Tibotec Pharmaceuticals Ltd. (IE) | 2009-10-28 | — | — | EP | disclosed |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| EP-2097402-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009080836-A2 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
| US-20090062311-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-7470664-B2 | HCV NS3 protease inhibitors | MERCK & CO., INC. (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2008135488-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008096001-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096002-A1 | HCV INHIBITING MACROCYCLIC PHOSPHONATES AND AMIDOPHOSPHATES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008092955-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1924593-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008059046-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-05-22 | — | — | WO | disclosed |
| EP-1912997-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910404-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007014925-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015787-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015855-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| WO-2006110471-A2 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | ASPEN AEROGELS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229374-A1 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | MIDCAP FUNDING IV TRUST | 2006-10-12 | — | — | US | disclosed |
| US-20060229374-A1 | MICROPOROUS POLYDICYCLOPENDIENE-BASED AEROGELS | MIDCAP FUNDING IV TRUST | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027071-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | PTPN1 2152/4885PTPRC 927/4885PTPRF 1050/4885 |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | PREP, SPINT2, PEPD | PTPN1 2187/4885PTPRC 917/4885PTPRF 1037/4885 |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | PTPN1 461/4885PTPRC 628/4885PTPRF 2903/4885 |
| US-12410146-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | PTPN1 2189/4885PTPRC 1100/4885PTPRF 1688/4885 |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | COPB1, HAVCR2, NOD1 | PTPN1 248/4885PTPRC 1078/4885PTPRF 1583/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20100173939-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, EIF2AK2 | PTPN1 3103/4885PTPRC 1585/4885PTPRF 1799/4885 |
| US-20220177409-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BCL3, XIAP | PTPN1 3345/4885PTPRC 1507/4885PTPRF 1984/4885 |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | PTPN1 2189/4885PTPRC 1100/4885PTPRF 1688/4885 |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CBR1, HCCS, CYP2B6 | PTPN1 1377/4885PTPRC 2241/4885PTPRF 3674/4885 |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, EIF2AK2 | PTPN1 1937/4885PTPRC 567/4885PTPRF 1030/4885 |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | IDO1, HCCS, IDO2 | PTPN1 1111/4885PTPRC 1202/4885PTPRF 2551/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20130018205-A1 | PROCESS FOR PREPARING CYCLOHEPTENE | DHPS, FDFT1, MTHFD2 | PTPN1 4751/4885PTPRC 4341/4885PTPRF 4861/4885 |
| US-20100022578-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, HCCS, IFNAR1 | PTPN1 1253/4885PTPRC 996/4885PTPRF 2722/4885 |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, CCNI | PTPN1 2572/4885PTPRC 1624/4885PTPRF 2748/4885 |
| US-12202782-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BCL3, XIAP | PTPN1 3345/4885PTPRC 1507/4885PTPRF 1984/4885 |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | HAVCR2, HCCS, CYP7A1 | PTPN1 1347/4885PTPRC 1414/4885PTPRF 2976/4885 |
| US-20230220179-A1 | Processes for Producing Cyclic Olefins from Polymers and Re-Polymerization Thereof | COASY, PTGIS, PUF60 | PTPN1 3743/4885PTPRC 2126/4885PTPRF 1843/4885 |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | PTPN1 2152/4885PTPRC 927/4885PTPRF 1050/4885 |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | NR4A1, NR4A3, NR4A2 | PTPN1 1466/4885PTPRC 1101/4885PTPRF 3253/4885 |
| US-20120238746-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | PREP, SPINT2, PEPD | PTPN1 2187/4885PTPRC 917/4885PTPRF 1037/4885 |
| US-20130217725-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | CBR1, HAVCR2, AOC1 | PTPN1 703/4885PTPRC 958/4885PTPRF 3233/4885 |
| US-10384987-B2 | 1,3-butadiene synthesis | SQLE, FDFT1, ENO1 | PTPN1 4601/4885PTPRC 4573/4885PTPRF 4451/4885 |
| US-20110112302-A1 | Metathesis Catalysts and Processes for Use Thereof | FASN, LIPC, MGLL | PTPN1 3993/4885PTPRC 2030/4885PTPRF 3489/4885 |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | IDO1, HCCS, CCNI | PTPN1 2572/4885PTPRC 1624/4885PTPRF 2748/4885 |
| US-20110112304-A1 | Carbene Complexes of Lithium And/Or Magnesium Metal Salts, And Uses Thereof | MCOLN2, CCNT1, MCOLN1 | PTPN1 2165/4885PTPRC 1345/4885PTPRF 3068/4885 |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HCCS, CBR1, CYP2B6 | PTPN1 692/4885PTPRC 1209/4885PTPRF 3027/4885 |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | NR4A1, NR4A3, NR4A2 | PTPN1 1592/4885PTPRC 1294/4885PTPRF 3367/4885 |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | SQLE, FDFT1, ENO1 | PTPN1 4601/4885PTPRC 4573/4885PTPRF 4451/4885 |
| US-20130338402-A1 | PROCESS FOR PREPARING MACROCYCLIC KETONES | AKR1C4, AKR1C1, AKR1C3 | PTPN1 4820/4885PTPRC 3420/4885PTPRF 4569/4885 |
| US-20090062311-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | HCCS, NR5A1, NR0B1 | PTPN1 1154/4885PTPRC 1313/4885PTPRF 3492/4885 |
| US-20210179570-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | PTPN1 2189/4885PTPRC 1100/4885PTPRF 1688/4885 |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | NUDT1, PNP, SLC28A1 | PTPN1 305/4885PTPRC 1690/4885PTPRF 1475/4885 |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | PTPN1 2152/4885PTPRC 927/4885PTPRF 1050/4885 |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, HCCS, CYP3A7 | PTPN1 1262/4885PTPRC 1140/4885PTPRF 2764/4885 |
| US-11325891-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | PTPN1 2189/4885PTPRC 1100/4885PTPRF 1688/4885 |
| US-20120171157-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2B6, SRD5A1, NR5A2 | PTPN1 1063/4885PTPRC 1037/4885PTPRF 2364/4885 |
| US-20240109851-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | PTPN1 2189/4885PTPRC 1100/4885PTPRF 1688/4885 |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20140113929-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | HCCS, HAVCR2, IFNAR1 | PTPN1 1461/4885PTPRC 1440/4885PTPRF 3218/4885 |
| US-20130089520-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20150141602-A1 | PROCESS FOR TREATING A DICYCLOPENTADIENE MONOMER | DHPS, UROD, ALAD | PTPN1 4440/4885PTPRC 4277/4885PTPRF 4612/4885 |
| US-20150315223-A1 | Ruthenium Complexes Comprising an Asymmetrical Unsaturated N-Heterocyclic Diaminocarbene | ORC3, RFC3, NCOA3 | PTPN1 3868/4885PTPRC 2091/4885PTPRF 4436/4885 |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, IDO2 | PTPN1 1111/4885PTPRC 1202/4885PTPRF 2551/4885 |
| US-20120202859-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | HCCS, HAVCR2, CCNI | PTPN1 2293/4885PTPRC 749/4885PTPRF 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.